< Back to Article

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Table 2

KRAS Exon 2 Mutations Found in Non-Small-Cell Lung Cancers Refractory to Treatment with Gefitinib or Erlotinib

doi: https://doi.org/10.1371/journal.pmed.0020017.t002